Roche: lung cancer drug succeeds in late-stage study
(CercleFinance.com) - Roche said Tecentriq helped patients suffering from advanced lung cancer to live longer, in an ongoing late-stage study.
A Phase III study met its co-primary endpoint of overall survival at interim analysis and showed that initial treatment with the combination of Tecentriq and Avastin plus chemotherapy helped people with advanced non-squamous non-small cell lung cancer (NSCLC) live significantly longer compared with Avastin plus chemotherapy alone, the firm said.
The Swiss drugmaker plans to submit this data to health authorities, including the US Food and Drug Administration and European Medicines Agency.
The multicenter, randomised trial enrolled 1,202 people.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
A Phase III study met its co-primary endpoint of overall survival at interim analysis and showed that initial treatment with the combination of Tecentriq and Avastin plus chemotherapy helped people with advanced non-squamous non-small cell lung cancer (NSCLC) live significantly longer compared with Avastin plus chemotherapy alone, the firm said.
The Swiss drugmaker plans to submit this data to health authorities, including the US Food and Drug Administration and European Medicines Agency.
The multicenter, randomised trial enrolled 1,202 people.
Copyright (c) 2018 CercleFinance.com. All rights reserved.